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Background: Cytochrome c (Cyt c) is an apoptosis-initiating protein when released into the cytoplasm of eukaryotic
cells and therefore a possible cancer drug candidate. Although proteins have been increasingly important as
pharmaceutical agents, their chemical and physical instability during production, storage, and delivery remains a
problem. Chemical glycosylation has been devised as a method to increase protein stability and thus enhance their
long-lasting bioavailability.
Results: Three different molecular weight glycans (lactose and two dextrans with 1 kD and 10 kD) were
chemically coupled to surface exposed Cyt c lysine (Lys) residues using succinimidyl chemistry via amide bonds.
Five neo-glycoconjugates were synthesized, Lac4-Cyt-c, Lac9-Cyt-c, Dex5(10kD)-Cyt-c, Dex8(10kD)-Cyt-c, and Dex3
(1kD)-Cyt-c. Subsequently, we investigated glycoconjugate structure, activity, and stability. Circular dichroism (CD)
spectra demonstrated that Cyt c glycosylation did not cause significant changes to the secondary structure, while
high glycosylation levels caused some minor tertiary structure perturbations. Functionality of the Cyt c glycoconjugates
was determined by performing cell-free caspase 3 and caspase 9 induction assays and by measuring the
peroxidase-like pseudo enzyme activity. The glycoconjugates showed ≥94% residual enzyme activity and 86 ± 3 to
95 ± 1% relative caspase 3 activation compared to non-modified Cyt c. Caspase 9 activation by the glycoconjugates
was with 92 ± 7% to 96 ± 4% within the error the same as the caspase 3 activation. There were no major changes in
Cyt c activity upon glycosylation. Incubation of Dex3(1 kD)-Cyt c with mercaptoethanol caused significant loss in the
tertiary structure and a drop in caspase 3 and 9 activation to only 24 ± 8% and 26 ± 6%, respectively. This demonstrates
that tertiary structure intactness of Cyt c was essential for apoptosis induction. Furthermore, glycosylation protected Cyt
c from detrimental effects by some stresses (i.e., elevated temperature and humidity) and from proteolytic degradation.
In addition, non-modified Cyt c was more susceptible to denaturation by a water-organic solvent interface than its
glycoconjugates, important for the formulation in polymers.
Conclusion: The results demonstrate that chemical glycosylation is a potentially valuable method to increase Cyt c
stability during formulation and storage and potentially during its application after administration.
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Development of efficient cancer treatments is a top prior-
ity in health related research. One of the most common
available options, in particular to treat advanced stages or
as post-operation treatment, is chemotherapy which still
today mostly employs extremely cytotoxic drugs that kill
metabolically active cells. Such drugs include alkylating* Correspondence: kai.griebenow@gmail.com
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unless otherwise stated.agents (e.g., cis-platin), anti-metabolites (e.g., 5-fluor ura-
cil, gemcitabine), anti-microtubule agents (e.g., pacli-
taxel), and topoisomerase inhibitors (e.g., doxorubicin).
Unfortunately, all these drugs have low tumor specificity
and a frequently narrow therapeutic index thus produ-
cing significant unwanted side effects [1,2]. This situ-
ation has resulted in an intense search for cancer drugs
that are more tumor-targeted and less toxic to normal
cells [3-11]. As the result, a set of tumor-targeted nano-
medicines is currently being studied that exploit hall-
marks of cancer for reviews see references [12-14].
Targeting mechanisms include coupling of cytotoxicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pressed receptors, formulation as nanoparticles to ex-
ploit the enhanced permeability and retention (EPR)
effect, drugs specifically targeting enzymes involved in
ontogenesis, among others [15-20]. Drug molecules in-
volved in this area include small molecules, peptides,
proteins, RNA molecules, and even complete oncolytic
viruses [21-23].
Proteins are a potentially attractive class of drugs be-
cause they can be used to exploit the hallmarks of can-
cer by targeting specific events. One hallmark is that in
cancer cells, particularly cancer stem cells, apoptosis is
frequently disabled [22,24]. Delivery of a molecule to the
cell switching apoptosis back on is therefore a potential
treatment strategy. Cyt c is exactly such a molecule. It is
a small mitochondrial heme protein involved in the in-
trinsic apoptotic pathway [24]. Severe DNA damage in
cells and other events such as increase in P53, oxidative
stress, and hypoxia lead to the activation of the intrinsic
apoptotic pathway, which involves formation of pores in
the mitochondrial membrane by BAX, BAK, and SMAC
[25,26]. The BH3-only domain proteins directly bind
and activate mitochondrial-localized BAK and BAX, trig-
gering BAK/BAX oligomerization and inhibition of
BCL-XL proteins [27,28]. The resulting depolarization of
the mitochondrial membrane induces the release of Cyt
c and other apoptotic factors into the cytoplasm [29].
Cyt c then interacts with the protein Apaf-1 to form the
apoptosome [24].
Apoptosis is absent in many cancer cells for multiple
reasons including mutation of critically important ele-
ments upstream from the event involving Cyt c [30].
Thus, a valid strategy is the delivery of Cyt c directly to
the cytosol of cancer cells to induce apoptosis and eradi-
cate the tumor. Using cancer models this has been ac-
complished multiple times by delivering Cyt c from
nanoparticles [30-32] but it is yet unclear whether such
systems would be sufficiently effective to allow for can-
cer treatment under real conditions. For example, uptake
of nanoparticles frequently involves receptor-mediated
endocytosis and thus the protein is exposed to condi-
tions of low pH and proteases in lysosomes prior to the
necessary endosomal escape [33-35]. Furthermore, the
interstitium of tumors is frequently rich in proteases that
are detrimental to pharmaceutical proteins [12,36].
In addition to aforementioned specific reasons, devel-
opment of effective protein formulations is a significant
challenge in the biopharmaceutical industry due to the
inherent chemical and physical instability of proteins
during production and purification [37], formulation
[38], storage [39,40], transportation [39,41], and admin-
istration [42]. Particularly challenging is the develop-
ment of smart drug-delivery and release systems for
protein drugs in this context, because they typically relyon immobilization of the drug in the carrier [43,44]. The
immobilization frequently employs linkers with pH- or
redox-sensitive bonds that are cleaved in the cell but
many proteins are structurally sensitive to the linker at-
tachment, as we have demonstrated recently for car-
bonic anhydrase [45] and also for Cyt c [46].
Improving the stability of pharmaceutical proteins
under the many different aforementioned circumstances,
in particular during delivery, likely requires covalent
strategies. One current example of such strategies con-
sists in modifying FDA approved protein drugs with
poly(ethylene glycol) (PEG) to afford increased plasma
life time and reduced immunogenicity [16,47]. However,
PEGs have not been reported to significantly stabilize
proteins thermodynamically [48]. Also, PEGs are not
biodegradable and can in tendency accumulate in the
body [49]. A possible biodegradable alternative to modi-
fication of proteins with PEG is the covalent modifica-
tion with carbohydrates. Chemical as opposed to natural
glycosylation has recently been used as a strategy to
stabilize commercially available medicines (i.e., glycosyl-
ated erythropoietin alfa (ARANESP®) and glycosylated
brain natriuretic peptide (NATRECOR®) [50,51].
We have in recent years introduced chemical modifica-
tion to stabilize several model proteins. We have systemat-
ically investigated the structure, function, dynamics, and
stability interrelationships in the neo-glycoconjugates ob-
tained [52-56]. We found that glycosylation of many model
proteins provides the advantages typically associated with
PEGylation but we also found significantly increased
thermodynamic stability [57]. In this work we set out to in-
vestigate in more detail the stability, functional, and struc-
tural consequences of chemical protein glycosylation using
for the first time a cancer relevant pharmaceutical protein,
namely, Cyt c. We are able to demonstrate that chemical
glycosylation is a potentially very useful method to stabilize
Cyt c in pharmaceutical applications.
Results and Discussion
Our strategy was to attach sugars via suitable linker
chemistry to the ε-amino groups of lysine residues of
Cyt c to establish various glycoconjugates. In order to vary
the glycan size in our experiments, we chose dextran with
molecular weights of 1 kD and 10 kD and lactose (0.5 kD)
as glycans. The 10 kD dextran was first activated by
reductive amination followed by modification with a
homo-bifunctional linker to form amine reactive mono-
(dextranamido)-mono-(succinimidyl)suberate (NHS-Dex,
10 kD) as described by us [52-55]. However, this did not
work for the small dextran because the precipitation step
failed. Thus, we used established 1-ethyl-3-[3-dimethyla-
minopropyl]carbodiimide hydrochloride (EDC)/N-hydro-
xysuccinimide (NHS) crosslinking chemistry with dextran
hexanoic acid (Dex-COOH) to form NHS-Dex (1 kD).
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was used as supplied. The amine and succinimidyl func-
tionalization of the dextrans was followed by FTIR and
NMR spectroscopy as described by us [52-55]. The acti-
vated sugars were then coupled to available amines of Cyt
c (Figure 1) as previously described by us for various pro-
teins [46,52-56].
The neo-glycoconjugates obtained were characterized
(Table 1). Five different conjugates were obtained with
the three different glycans. Throughout the manuscript
we adopt the following nomenclature: Cyt c modified at
4 and 9 lysine residues with lactose was named Lac4-Cyt
c and Lac9-Cyt c; Cyt c modified at 5 and 8 lysine resi-
dues with dextran of 10 kD were named Dex5(10kD)-
Cyt c and Dex8(10kD)-Cyt c; and the glycoconjugate
with 3 lysine residues modified with dextran of 1 kD was
named Dex3(1 kD)-Cyt c. Glycosylation did not affect
the pseudo-enzyme activity even for the most heavily
glycosylated sample (Dex8(10kD)-Cyt c) in which there
was a total of 80 kD of glycan attached to the roughly 13
kD protein. We can surmise that structure of Cyt c was
likely not affected by binding of the sugars and that the
substrate could still relatively freely diffuse to the active
site even in the presence of a “sugar shell”.
The use of Cyt c as an anti-cancer drug depends on the
formation of the Apaf-1/Cyt c complex (apoptosome),
which is responsible for the activation of the caspase cas-
cade leading to apoptosis. Electrostatic interactions be-
tween positively charged lysine residues of Cyt c at the
exposed heme edge and the WD-40 region of Apaf-1 are
critically important to facilitate Cyt c-to-Apaf-1 binding
[58,59]. Thus, it is imperative to preserve the Cyt c con-
formation subsequent to any chemical modification to as-
sure that Cyt c is still able to bind to Apaf-1 and induce
apoptosis. We performed a cell-free caspase 3 and 9 assays
since Cyt c is a cell-membrane impermeable protein
[30,31,60]. After the freeze and thaw cycles the lysate wasFigure 1 Representation of the chemical glycosylation of Cyt c usingcentrifuged at 10,000 g to ensure mitochondrial removal.
This is important to avoid false positives from mitochon-
drial leakage of Cyt c. Furthermore, we added the sub-
strates to the lysates as controls and subtracted any small
absorbance developing from the samples to which the ex-
ternal Cyt c or Cyt c glycoconjugates was added. The data
obtained (Table 1) show that at most levels of glycosyla-
tion the bioactivity of Cyt c was still ca. 90% compared to
non-modified Cyt c. This result is in thus far remarkable
as there are lysine residues in the putative Cyt-c-Apaf-1
binding epitope. We have reported a similar finding albeit
with Lac4-Cyt c and Cyt c-Lac4-SPDP for Cyt c activity on
HeLa cells [46].
There are several potential explanations for this that
need to be verified by site-directed glycosylation (cur-
rently ongoing in our laboratory). First, glycosylation
could be inefficient for Lys residues in the Apaf-1 inter-
action epitope. We have highlighted why we believe this
is happening in Additional file 1. Second, glycosylation
could make Cyt c intrinsically more reactive and this
could compensate for activity loss by glycosylation of
residues in the interaction epitope. Third, glycosylation
might not prevent Cyt c binding to Apaf 1 because ionic
interactions are long-range. Regardless of the mechanis-
tic reason, however, even highly glycosylated Cyt c was
still remarkably active in activating the caspase cascade.
To investigate the structural consequences of glycan
binding to Cyt c, we performed circular dichroism (CD)
spectroscopy. Three spectral regions were investigated:
the far-UV CD region from 200–280 nm which is sensi-
tive to secondary structural perturbations, the near UV-
CD region from 260–320 nm which is sensitive to ter-
tiary structure perturbations, and the Soret region of
heme absorbance from 380 to 460 nm which is sensitive
to the heme environment and thus the structure of the
heme binding pocket (Figure 2). In the far UV-CD re-
gion only minor spectral and thus secondary structuralmonofunctionally activated glycans.
Table 1 Functionality determination for Cyt c glycoconjugates
Protein
formulation
Glycosylation degree# Residual activity$ (%) Caspase 3 activation% (%) Caspase 9 activation% (%) Degradation rate,
Kd
& (x 10−2 min−1)
Cyt c N/A 100 100 100 10.3 ± 0.1
Lac4-Cyt c 4.4 ± 0.4 94 ± 4 95 ± 1 95 ± 9 9.9 ± 0.2
Lac9-Cyt c 9.3 ± 0.2 97 ± 2 86 ± 3 93 ± 8 9.6 ± 0.1
Dex3(1 kD)-Cyt c 3.4 ± 0.9 98 ± 1 91 ± 2 96 ± 4 9.8 ± 0.2
Dex5(10kD)-Cyt c 5.2 ± 0.8 93 ± 4 89 ± 1 94 ± 6 9.5 ± 0.1
Dex8(10kD)-Cyt c 8.3 ± 0.4 95 ± 3 85 ± 2 92 ± 7 9.9 ± 0.3
#Glycosylation degree refers to the number of glycan modified Cyt c lysine residues as determined by 2,4,6-trinitrobenzene sulfonic acid (TNBSA) assay. $The
residual activity was calculated with respect to the specific activity of native Cyt c.%The caspase 3 and caspase 9 activation is with respect to the activation
induced by non-modified Cyt c. The substrates used for caspase-3 and caspase-9 activation assay were 10 mM DEVD-pNA and 4 mM LEHD-pNA, respectively. &The
rate of degradation was calculated for Cyt c and Cyt c glycoconjugates after exposure to 1.5 mM H2O2. Each experiment was performed in triplicate, the values
averaged, and the ± values are the calculated SD.
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were evident when investigating the glycoconjugates in
spectral regions that are sensitive to tertiary structural
changes. The near UV-CD spectra of Cyt c and the lac-
tose glycoconjugates were similar, while the dextran bio-
conjugates showed a reduced signal, which can be
interpreted as being indicative of less tertiary structure
(Figure 2B). Nevertheless, the CD spectra in the heme
absorption region (Figure 2C) all showed a pronounced
cotton effect, which is typical for a native heme environ-
ment. The Cotton effect, named after its discoverer
Aimé Cotton (1869–1951), is the characteristic change
in circular dichroism in the vicinity of an absorption
band of a substance characterized by a positive and
negative CD signal and a zero crossing at the absorption
maximum. Structural changes in the heme-binding
pocket lead to the disappearance of the cotton effect as
reported by others and us for Cyt c [46,61]. This is in
agreement with the activity data in Table 1, which show
that all bioconjugates had a similar pseudo enzyme ac-
tivity than Cyt c. We can surmise that for all bioconju-
gates the structure was native-like with the exception of
a somewhat more lose tertiary structure packing in case
of the dextran conjugates.
Next we proceeded to study the Cyt c stability in se-
lected experiments. Chemical glycosylation has been
shown to assist in overcoming chemical protein instabil-
ity and provide protection against proteases [62-64].
This is highly relevant since it has been established that
the tumor interstitial space presents significant trypsin-
like protease activity and also oxidative stress [36].
Trypsin-like activity is particularly harmful to the integ-
rity of basic proteins. The proteolytic degradation in tu-
mors enables cell movement and the metastatic spread
[31,65]. Potential improvement of Cyt c stability towards
the tumor environment by glycosylation was tested by
tryptic and chymotryptic assays.
The results of the tryptic digestion are shown in
Figure 3. As anticipated, trypsin had a devastating effecton Cyt c integrity. Glycosylation stabilized the protein
against proteolysis. It is evident that the amount of gly-
can bound to the protein is more significantly related to
protection against proteolysis than the size of the bound
glycan. For example, Lac9-Cyt c and Dex8(10kD)-Cyt c
show similar protection from trypsin degradation even
though there is about 20 times more glycan bound per
weight in the dextran containing bioconjugate. This can
be understood because trypsin cuts the peptide back-
bone next to Lys or Arg residues and the more Lys resi-
dues are chemically blocked, the lower the propensity
for the proteolytic event to happen [66].
To obtain a better idea of whether glycans in gen-
eral protect Cyt c from proteolytic degradation by
steric shielding, we also performed digestion with α-
chymotrypsin, which cuts preferentially next to aro-
matic residues. We employed those samples for which
glycosylation provided the best protection in the
tryptic assay (Figure 3). It is evident that glycosylation
protected Cyt c from proteolysis, albeit to a much
lesser degree than in the tryptic assay (Figure 4). We
can therefore conclude that glycosylation protects Cyt
c from proteolytic degradation in general, but much
better against those proteases having a binding pocket
selective for Lys.
In summary, glycosylation should provide some pro-
tection against proteolytic degradation in the tumor in-
terstitium and possibly after endocytosis of suitable
constructs in lysosomes in agreement with our recent
data using HeLa cells [46].
Cancer tissues frequently display an increased level of
reactive oxygen species and oxidative stress as a result of
persistent chronic inflammation [67]. The in vivo degrad-
ation of proteins by H2O2 interferes with normal cellular
function, accelerates aging, and enhances metabolism of
carcinogens [68,69]. Higher levels of free radicals also in-
duce DNA mutations, which promote cancer progression
and development of resistance [70]. To test whether gly-
cosylation could protect the protein from oxidative stress,
Figure 2 Far UV (A), near UV (B), and heme (C) region CD
spectra of 0.6 mg/ml Cyt c and Cyt c glycoconjugates in
100 mM phosphate buffer at pH 7.4 and 20°C.
Figure 3 Degradation of Cyt c and Cyt c glycoconjugates by
4 mg/ml trypsin at 37°C. Each experiment was performed in
triplicate, the values averaged, and the error bars are the calculated SD.
Figure 4 Degradation of Cyt c and Cyt c glycoconjugates by
5 mg/ml α-chymotrypsin at 37°C. Each experiment was performed
in triplicate, the values averaged, and the error bars are the
calculated SD.
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which attacks the S-S bridge that covalently couples the
heme group to apo Cyt c thus promoting unfolding
[61,71,72]. The rate of degradation (Kd) was determined
from the decaying heme Soret absorbance (Table 1). No
significant effect was found in this instance and chemical
degradation by Cyt c with the small molecule H2O2 was
not significantly slowed down. Therefore, it might be of
value to protect Cyt c from the oxidative stress in tumor
tissues by packaging it inside a delivery vehicle. Theexperiment also provides some insight into the effect of
glycosylation on Cyt c structural dynamics or compact-
ness of the folded state. The CD experiments revealed that
Cyt c was not packed more densely as the result of glyco-
sylation (Figure 2B) in contrast to what we have found for
some other proteins [52-57]. This is not unexpected since
Cyt c is intrinsically already very stable and not dynamic.
The lack of an effect of sugars to stabilize Cyt c by redu-
cing structural dynamics (molecular breathing) against the
small molecule H2O2 is in agreement with the CD data.
We have previously reported that chemical protein
glycosylation was able to reduce moisture-induced ag-
gregation of chymotrypsin under accelerated conditions
[73], which is pharmaceutically relevant once vials or
formulations of pharmaceutical proteins are exposed to
moisture [74]. One has to keep in mind that this
phenomenon is not only relevant to the exposure of
Figure 6 The effect of incubation at 50°C on the structure of
Cyt c. After incubation, the glycoconjugates were lyophilized and
dissolved in 10 mM phosphate buffered saline at pH 7.3. Each
experiment was performed in triplicate, the values averaged, and the
error bars are the calculated SD.
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and dehydrated vials under atmospheric conditions, but
also applies to the slow rehydration of dehydrated pro-
teins inside of drug delivery systems [75]. Water fre-
quently cannot penetrate the interior of drug delivery
systems that are based on hydrophobic materials (e.g.,
poly(lactic-co-glycolic) acid) and encapsulated proteins
are rehydrated slowly upon polymer swelling and
degradation.
Cyt c and Cyt c glycoconjugates were exposed to ac-
celerated storage conditions of high humidity (75% rela-
tive humidity) (Figure 5) and high temperature (50°C)
(Figure 6) for 72 h. It is evident that glycosylation sub-
stantially reduced the susceptibility of Cyt c to the heat
and moisture stresses.
The stabilization of Cyt c towards moisture (Figure 5)
was related to the amount and size of the glycan at-
tached. The disaccharide lactose had only little effect on
improving Cyt c stability at the lowest ratio. Increasing
the amount of that glycan attached to Cyt c improved its
stability. In contrast, dextran with a MW of 10 kD prac-
tically completely prevented Cyt c degradation by mois-
ture already when five molecules were bound.
Similarly, denaturation by heat was prevented the
more efficiently the more glycan was bound to Cyt c and
the larger the sugar entity (Figure 6). Our interpretation
for the data is that the Cyt c surface was shielded by the
glycans and that this reduced protein-protein interac-
tions which can cause irreversible denaturation events.
Regardless of the exact mechanism, it is clear that the
Dex8(10kD)-Cyt c was the most stable preparation, in
particular under elevated temperature conditions.
Finally, we also aimed at assessing the effect of exposure
of Cyt c to an organic solvent interface. Such interfacesFigure 5 The effect of 75% relative humidity on the structure of
Cyt c and its glycoconjugates. After incubation, the glycoconjugates
were lyophilized and dissolved in 10 mM phosphate buffered saline at
pH 7.3. Each experiment was performed in triplicate, the values
averaged, and the error bars are the calculated SD.are common when preparing protein nanoparticles by
precipitation [76] or upon protein encapsulation into
hydrophobic polymers, e.g., by the water-in-oil-in-water
double emulsion technique [77]. We selected one repre-
sentative sample (Dex3(10 kD)-Cyt c) and two solvents
previously employed in nanoparticle preparation following
solvent precipitation protocols, i.e., acetone and aceto-
nitrile [76]. Using various ratios, we found that 1:2 and 1:4
water-to-acetonitrile volume ratios were sufficient to in-
duce Cyt c precipitation and result in stable suspensions.
Next we tested the effect of the protein-solvent interface
on the capacity of Cyt c to induce in vitro caspase 3 acti-
vation in a cell-free system (Table 2). Therapeutic use of
Cyt c in cancer applications relies on the induction of
apoptosis after the protein was delivered to the cytoplasm
[24,26,58]. The results demonstrate that Cyt c suffered sig-
nificant activity loss when precipitated with acetonitrile
and acetone (Table 2). In contrast, glycosylation prevented
inactivation completely for both solvents. We interpret
the results as being indicative for the glycan preventing
Cyt c – organic solvent interface interactions, which are
typically initiated by hydrophobic protein surface patches
and driven by entropic effects [78].
While the Cyt c functionality upon contact with the
two organic solvents was maintained regardless of the
desolvating agent used, SEM images show differences in
the particle properties after the precipitation process
(Figure 7). SEM images of Dex3(1kD)-Cyt c show that
the powder particles obtained with both solvents had a
spherical shape and that the particle size was in the
nanometer range. However, particles obtained by using
acetone were smaller and more homogeneous than those
obtained with acetonitrile. For drug delivery applications
Table 2 Results of the capability of Cyt c and Dex3(1 kD)-Cyt c to activate apoptosis after their exposure to
water-organic solvent (o/w) interface conditions
Protein Desolvating agent Relative caspase 3 activation# (%)
Cyt c Acetonitrile 64 ± 8
Acetone 51 ± 2
Dex3(1 kD)-Cyt c Acetonitrile 100 ± 4
Acetone 100 ± 3
#The relative activity was calculated with respect to the caspase 3 activation induced by Cyt c/Apaf-1 complex.
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homogeneity are desirable [19].
From our data we can surmise that chemical Cyt c gly-
cosylation is a very useful approach to protect the pro-
tein from various stresses that are typically associated
with pharmaceutical production processes and the deliv-
ery. Even though we have not conducted detailed mech-
anistic studies in this work, the data are consistent with
the glycans providing protection in an amount and size
dependent manner. The larger the glycan and the more
attached to Cyt c, the better the protection. It is likely
that the protection afforded is due to a combination of
effects, i.e., restriction of the conformational space, re-
duction of solvent accessible area, and avoiding protein-
solvent hydrogen bonds, as previously suggested by us
[52-57] and others [49,62-64].
Conclusions
Protein instability is a major factor limiting their use in
pharmaceutical applications. Herein we explored how
the covalent attachment of lactose and dextran via
amine-directed linker chemistry affects the stability of
Cyt c. Cyt c is a protein with good potential in cancer
applications since it can be utilized to induce apoptosis
upon intracellular delivery. We show that glycosylation
does not negatively affect the capability of Cyt c to in-
duce apoptosis. Furthermore, glycosylation improves the
stability of Cyt c towards many stress factors relevant toFigure 7 Scanning electron microscopy (SEM) images of lyophilized D
with (A) acetonitrile and (B) acetone as desolvating agent.the formulation, storage, and delivery of the protein into
the cancer tumor microenvironment. We conclude that
glycosylation should be a very useful method for improv-




Cytochrome c from equine heart (EC 232-700-9), dextran
from L. mesenteroides (EC 232–6775, average Mw = 9–11
kD), trypsin from porcine pancreas, α-chymotrypsin type
II from bovine pancreas, caspase 3 substrate (DEVD-
pNA), caspase 9 substrate (LEHD-pNa), disuccinimidyl
suberate linker, protease inhibitor cocktail, 2,2’-azino-bis
(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), ammo-
nium carbonate, dimethyl sulfoxide (DMSO), methylene
chloride, acetone, and acetonitrile (HPLC grade) were
from Sigma-Aldrich (St. Louis, MO). Mono-(lactosyla-
mido)-mono-(succinimidyl) suberate (NHS-Lac) and dex-
tran hexanoic acid (Dex-COOH, MW= 1 kD) were from
Carbomer (San Diego, CA). Cellulose ester dialysis mem-
branes were from Spectrum (Rancho Dominguez, CA).
EDC and NHS were from Proteochem (Denver, CO). A
caspase-3 activity assay (CaspACE™ assay) was purchased
from Promega (Madison, WI). HeLa cells, sera and culture
media were purchased from the American Type Culture
Collection (Manassas, VA). All other chemicals were from
various commercial suppliers and were of analytical grade.ex3(1 kD)-Cyt c after the precipitation via solvent displacement
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The synthesis of amine-reactive glycans was performed
as previously established [52,78-80]. Synthesis of mono-
(dextranamido)-mono-(succinimidyl) suberate (NHS-
Dex, 10 kD) consisted of selective amination followed by
succinnylation. Dextran (10 kD) (10.0 g, 1.0 mmol) and
ammonium carbonate (2.0 g, 21.74 mmol) in nanopure
water (50.0 ml) were stirred at 10°C for five days. After-
wards ammonium carbonate was removed by dialysis
(MW cut-off 100 D) for 48 h and the solution was lyoph-
ilized to afford 1-amino-dextran. To achieve dextran
succinnylation, 1-hydroxy benzotriazole (0.675 g, 5.0 mmol)
and disuccinimidyl suberate (1.841 g, 5.0 mmol) were dis-
solved in DMSO (60 ml) and heated to 80°C for 5 min.
After cooling, 1-amino-dextran (5.0 g, 0.5 mmol) was
added and the reaction maintained at 20°C for 24 h. The
product was precipitated by addition of CH2Cl2 (200 ml)
pelleted by centrifugation (1,500 rpm) at 4°C for 15 min.
The resulting white precipitate was lyophilized to afford
NHS-Dex (10 kD) in quantitative yield.
Amine-reactive functionalization of Dex-COOH
Dex-COOH is chemically reactive to carbodiimides. Thus,
EDC/NHS crosslinking chemistry was used to form the
amine reactive NHS-Dex 1 kD to directly couple it to pri-
mary amines of Cyt c as described [81]. Briefly, 1 mg/ml
of Dex-COOH in 2- (N-morpholino) ethanesulfonic acid
(MES) buffer was reacted with 2 mM of EDC and 4 mM
of NHS for 20 minutes at room temperature. Immediately,
the glycosylation reaction was started for Dex (1kD)-Cyt c
glycoconjugate.
Glycosylation of Cyt c
Cyt c glycoconjugates were prepared by chemical glyco-
sylation with succinimidyl-activated glycans (NHS-Dex
(10 kD), NHS-Dex(1 kD) and NHS-Lac) as described by
us in detail previously [53]. Briefly, 100 mg of Cyt c was
dissolved in 20 ml of 100 mM phosphate buffer with
20 mM NaCl at pH 7.4. To achieve glycoconjugates with
two levels of glycosylation, Cyt c solutions were reacted
with an excess of 5 and 10 moles of NHS-Lac, an excess
of 8 and 15 moles of NHS-Dex(10 kD) and an excess of
5 moles of NHS-Dex(1 kD). The reaction was performed
for 1 h at room temperature under gentle stirring. Un-
bound glycans were removed by dialyzing thrice against
nanopure water at 4°C for 48 h. After the dialysis, all the
glycoconjugates were lyophilized for 48 h and then
stored at −20°C. The extent of modification was deter-
mined by TNBSA colorimetric assay as described [82,83].
Circular dichroism (CD) spectroscopy
CD spectra were recorded using an OLIS DSM-10 UV–
vis CD spectrometer at 21°C. Cyt c and Cyt c glycocon-
jugates were dissolved in 20 mM PBS at pH 7.4. CDspectra were acquired from 200 to 260 nm (secondary
structure), 260 to 320 nm (tertiary structure) and 380 to
450 nm (Soret region) at a concentration of 0.6 mg/ml
using quartz cuvettes of 0.2 to 10 mm path lengths. Each
spectrum was obtained by averaging six scans. Spectra
of buffer blanks were measured prior to the samples and
subtracted digitally using the software supplied with the
instrument.
Peroxidase pseudo-activity assay
The peroxidase-like activity of Cyt c was measured as
described [84]. Briefly, the reaction was followed photo-
metrically at 415 nm using 0.25 ml of 0.01 mg/ml Cyt c
or Cyt c glycoconjugates, 0.2 ml of 300 mM H2O2, and
0.55 ml of 0.05 mM ABTS in 20 mM potassium phos-
phate buffer at pH 7. In all cases the specific activity
(mM of ABTS+∙x min−1 × mg−1 Cyt c) was calculated. The
activity was obtained by plotting the time-dependent ab-
sorbance changes vs. time. The linear portions of the
graphs at less than 10% substrate conversion were used to
obtain the initial velocities (V0). The experiments were
performed in triplicate, the results averaged and the stand-
ard deviations calculated.
Moisture and temperature-induced structural instability
The study of the effect of moisture and heat on Cyt c in-
tegrity during storage was performed as described
[71,85]. Briefly, 0.60 mg/ml of Cyt c and Cyt c glycocon-
jugates in PBS at pH 7.4 (liquid-phase formulation) were
exposed to accelerated stress storage conditions. To
study moisture-induced instability, Cyt c and its glyco-
conjugates were incubated in a desiccator over NaCl salt
slush at 20°C (which corresponds to 75% relative humid-
ity) for 24, 48, and 72 h. To study heat- induced instabil-
ity of Cyt c, the samples were incubated in a heat
chamber at 50°C for 24, 48, and 72 h. After the desired
length of time, the incubated protein samples were re-
moved followed by 20 min of gentle stirring to ensure
dissolution of the samples. The degradation of Cyt c
samples was monitored at 408 nm [61,71,72]. Error bars
in the figure are the calculated standard deviations (SD).
Oxidative stress assay
The rate of Cyt c degradation upon exposure to oxidative
stress was monitored as previously described [61,71]. In
brief, 200 μl of 1.5 mM H2O2 was added to 1 ml of Cyt c
and Cyt c glycoconjugates (0.2 mg/ml) in 20 mM PBS
pH 7.4 at 21°C. Cyt c degradation was measured by
monitoring the rate of the decrease in the Soret band
absorbance at 408 nm after 10 min of incubation. The
degradation rate constant (Kd) was calculated from the
residual absorption versus time using first order kinet-
ics. The experiments were performed in triplicate, the
results averaged and the SD calculated.
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HeLa cells were maintained in accordance with the ATCC
protocol. Briefly, the cells were cultured in minimum essen-
tial medium (MEM) containing 1% L-glutamine, 10% fetal
bovine serum (FBS), and 1% penicillin in a humidified incu-
bator with 5% CO2 and 95% air at 37°C. All experiments
were conducted before cells reached 25 passages. During
each passage, cells were washed twice with PBS, detached
using trypsin, and resuspended in supplemented MEM.
Cell-free caspase 3 and caspase 9 activity assays
These assays were adopted from the literature [86]. In
brief, HeLa cells were grown to 80% confluency and har-
vested as described above (cell culture method). For dis-
ruption the cells were suspended in 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
buffer at pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM so-
dium EDTA, 1 mM sodium EGTA, 1 mM DTT, 250 mM
sucrose, and a protease cocktail inhibitors (serine, cysteine,
aspartic acid, and metalloprotease inhibitors) (1×). The
suspended cells were frozen in liquid N2 for 2 min and
thawed in a 37°C water bath and the freeze/thaw cycle re-
peated thrice. The lysate was centrifuged at 10,000 × g for
20 min to remove the mitochondria. The protein concen-
tration in the lysate was determined using the Bradford
assay [87]. The cell-free reactions were performed in
homogenizing buffer in a total volume of 100 μL. The
reaction was initiated by adding 100 μg/ml of Cyt c or
Cyt c glycoconjugates to freshly purified cytosol (3 mg/
ml of proteins). The reaction was incubated at 37°C for
150 min. Later, 20 μl of the reaction mixtures was with-
drawn and added to 78 μl of a mixture containing
100 mM HEPES at pH 7.5, 10% w/v sucrose, 0.1% w/v
CHAPS (3-[(3-cholamido-propyl)-dimethylammonio]-
1-propane-sulfonate), 10 mM DTT, and 2% v/v DMSO.
This mixture was prepared for caspase 3 or caspase 9
assay in two different 96-well plates. Caspase 3 activity
was measured using 2 μl of the substrate DEVD-pNA
(10 mM) and caspase 9 activity using 2 μl of the sub-
strate LEHD-pNa (4 mM). The plates were incubated
overnight at room temperature and the absorbance at
405 nm was measured for both assays using a micro-
plate reader (Thermo Scientific Multiscan FC). All mea-
surements were performed in triplicate.
Proteolytic assays
Protease degradation was performed as described by
Reinhardt et al. [88]. In brief for tryptic degradation,
0.16 mg/ml of Cyt c or Cyt c glycoconjugates in 20 mM
Tris–HCl at pH 8 were gently stirred for 20 min at 20°C.
Then, 4 mg of trypsin was added to 1 ml of each sample
and the mixture incubated at 37°C for 24, 48 and 72 h.
For chymotryptic degradation, 0.79 mg/ml of Cyt c or Cyt
c glycoconjugates in 20 mM Tris–HCl at pH 8 were gentlystirred for 20 min at 20°C. Then, 5 mg of chymotrypsin
was added to 1 ml of each sample and the mixture incu-
bated at 37°C for 24, 48, 72 and 96 h. For both assays, Cyt
c degradation was determined by measuring the absorb-
ance at 408 nm after the incubation times.
Protein precipitation by solvent displacement
A solvent displacement method similar to that described by
us [76] was performed to precipitate Cyt c and obtain nano-
particles. Briefly, 5.0 mg of Cyt c was solvent-precipitated
by adding 1.5 ml of acetonitrile to 1 ml of aqueous solution.
To precipitate the Dex(1 kD)-Cyt c conjugate the concen-
tration of the glycoconjugate was adjusted to 2.5 mg/ml
and the volume ratios to precipitate it with acetonitrile and
acetone were 1:2 and 1:1, respectively, in this case.
Scanning electron microscopy (SEM)
SEM of lyophilized Cyt c and Dex-Cyt c after protein pre-
cipitation was performed using a JEOL 5800LV scanning
electron microscope at 20 kV. The samples were coated
with gold for 10 sec using a Denton Vacuum DV-502A.
Additional file
Additional file 1: The Additional file 1 contains two figures (Figure
A1 and Figure A2) and discusses why we argue that chemical
glycosylation did not diminish the capability of Cyt c to activate
caspases 3 and 9. Figure A1 shows the effect of β-mercaptoethanol
exposure of Dex3(1 kD)-Cyt c on the far-UV CD, near-UV CD, and heme
region CD spectra. Figure A2 shows the crystal structure (1HRC.pdb) of
horse heart Cyt c including the solvent-exposed Lys residues.
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